HCA Healthcare Third Quarter 2026 Earnings Call - HCA HEALTHCARE INC

Explicit Guidance:

• Full-Year 2026 Adjusted EBITDA: Expected to land in the upper half of previously reaffirmed guidance ranges; full-year Medicaid supplemental payment net benefits expected between $600M and $800M (updated upward from prior estimates); unfavorable payer mix impact expected at or slightly above the upper end of the previously updated range.
• Full-Year 2027 Earnings: Anticipated to be generally consistent with 2026 levels, assuming no material policy changes beyond H.R. 1 and moving past the most significant payer mix effects from insurance exchanges.
• Long-Term Performance: Beyond 2027, performance expected to align with long-term growth targets, driven by strategic initiatives including digital transformation, network development, and resiliency programs.

Business-Segment Outlook:

• Volume Growth: Forecasted volume growth for 2027 is 2–3%, consistent with long-term thinking; demand for services expected to remain strong.
• Exchanges & Payer Mix: Expect fewer people to lose coverage on health insurance exchanges in 2027 compared to 2026, though a meaningful impact on payer mix is anticipated; exchange volume showed sequential improvement in Q3 2026 (up ~8% QoQ), but migration of lost exchange coverage to uninsured status continues (approx. 80% of uninsured volume growth).
• Surgical Volumes: Emergent surgical volumes expected to remain strong; elective surgery trends remain under pressure from macro forces (coverage, affordability) with no assumption of recovery or pickup until after the fourth quarter seasonality is analyzed.
• Revenue per Unit: Insured revenue per adjusted admission (excluding exchanges) expected to continue growing at a higher rate than the first half of the year, driven by commercial volume strength, solid rate growth, and improved collection yields.
• Cost Performance: Anticipated favorable cost performance for 2027 driven by operating leverage from volume growth and enterprise-wide resiliency programs.
• Medicaid Supplemental Payments: Net benefits expected to decrease by approximately $550M–$650M in 2027 versus 2026 due to the expiration of grandfathered state programs (e.g., Virginia, Florida, Georgia) related to prior-year services.

Market and Competitive Outlook:

• Demand Drivers: Underlying demand supported by population growth, aging baby boomers, chronic conditions, and new technology; company has gained market share incrementally across many markets.
• Network Expansion: Ambulatory platform nearing 3,000 units (including urgent care and ASCs); focus on creating convenience and accessible care sites to integrate patients into the acute care system.
• Capacity & Utilization: Inpatient occupancy running at all-time highs (~75%); adding beds and capacity within facilities; optimizing patient flow to create additional capacity.
• Competitive Positioning: No significant market exits anticipated; portfolio optimized over the last 7–8 years to focus on high-probability markets; opportunistic approach to new markets if affordability and execution models are met.
• Inpatient-Only List (IPOL): Phase 1 of 3-year phase-out focuses on orthopedics; some migration to outpatient observed, but company views outpatient market as more competitive; continuing investment in both inpatient and ASC platforms to navigate the shift.

Macro / Industry Outlook:

• Policy Environment (H.R. 1): Monitoring work requirements for able-bodied adults in expansion states (40% of Medicaid volume); estimated to impact 15–20% of Medicaid bond; anticipated modest impact on full-year 2027 earnings.
• Medicare Opt-out Rules (OPTS): Viewing the proposed rule as budget-neutral for 340b reallocation which could benefit for-profits; not sizing the public impact yet but viewing it as a potential positive factor for 2027.
• Affordability & Access: Coverage loss remains a primary macro force impacting elective care demand; 2027 guidance does not assume any stronger-than-normal tailwind from deductible resets in Q4 2026.
• Regulation: Continued monitoring of 1115 waivers requiring budget neutrality from a federal perspective; states continue to file applications with positive momentum.

Strategic Initiatives:

• Enterprise-Wide Resiliency Program: Ongoing multi-year initiative covering revenue integrity, asset optimization (patient flow), variable costs (labor, supplies), and fixed costs; viewed as a core operational capability rather than a one-time cost saver; digital transformation and shared service expansions (e.g., Parallon) cited as key enablers for future value.
• Digital Transformation: AI initiatives expected to create a better work environment for caregivers and enhance access.
• Capital Allocation: Capital expenditures totaled $1.36B in Q3; share repurchases of $3B in Q3; majority of authorized buyback program expected to be completed by year-end subject to market conditions; dividends of $165M in Q3.
• Debt Profile: Debt-to-adjusted EBITDA leverage remains in the lower half of the stated target range; balance sheet considered strong and well-positioned.

Risks and Headwinds to Outlook:

• Payer Mix Volatility: Continued migration of patients from exchange coverage to uninsured status remains a significant headwind; impact on adjusted EBITDA estimated at ~$400M in Q3 alone.
• Medicaid Payment Reductions: $550M–$650M reduction in supplemental net benefits in 2027 is a certainty based on 2026 grandfather approvals.
• Policy Uncertainty: Potential material policy changes beyond H.R. 1 or the finalization of CMS rules (OPTS, 1115 waivers) could alter the "generally consistent" 2027 outlook.
• Elective Care Recovery: No assumption of a rebound in elective surgical volumes until seasonality patterns in Q4 are confirmed; affordability and coverage constraints may persist.
• Planning Fluidity: 2027 guidance is preliminary, based on early planning assumptions, and subject to change as Q4 results and final enrollment data (Nov–Jan) become available.

Management Tone on the Future:

• Confidence: Management expresses strong confidence in the company's ability to achieve long-term objectives due to scale, critical role in communities, and disciplined culture ("strong staying power").
• Hedging: Frequent caveats regarding the early stage of planning for 2027; guidance for 2027 relies on assumptions that policy environment stabilizes and payer mix shifts resolve.
• Resilience: Emphasis on the "resiliency" of the business model, citing 22 consecutive quarters of volume growth and the ability to offset surgical weakness with growth in trauma, cardiac, and neonatal services.
• Forward-Looking: Tone is cautiously optimistic, acknowledging headwinds while highlighting structural strengths and the systematic nature of cost-saving initiatives.

Miscellaneous:

• Professional Fees: Identified as a continuing pressure point, up ~12% YoY, driven by radiology and anesthesiology; now represent ~24% of other operating expenses.
• Labor Costs: Expected to see a typical 100 basis point increase in expense per equivalent admission from Q2 to Q3 due to merit adjustments, though actual expenses were flat YoY and down 40 bps sequentially due to resiliency gains.
• Q&A Timing: Further detailed guidance for 2027 expected to be provided on the Fourth Quarter call in January, pending the completion of the fourth quarter and analysis of enrollment data.